M.O.S.T. Study Real World Results
Phase 4 Multi-center Open-label Study (M.O.S.T.) of Rhopressa® for the Reduction of Elevated IOP in Patients with OAG or OHT in a Real-world Setting
M.O.S.T. was a 12-week, prospective, multi-center, non-comparative, open-label study. This study was open to patients with open angle glaucoma or ocular hypertension, regardless of their current regimen.
Download the M.O.S.T. study leave-behind for additional information.
This video, featuring expert commentary from glaucoma specialists, focuses on the cohort of patients who received Rhopressa® as adjunctive therapy (n=161) – that is, concomitantly with one or more other IOP-lowering medications.